Effect of MD1003 (high dose pharmaceutical grade biotin) in progressive MS: Design and baseline data from the phase III SPI2 study

Authors
Category Primary study
ConferenceMultiple Sclerosis Journal
Year 2018
This article has no abstract
Epistemonikos ID: 7b3694f9270af61e696498df48ffa9162e624327
First added on: Apr 30, 2026